South Korea's Celltrion to Begin Mass Production of Experimental COVID-19 Antibody Drug Ahead of EUA Approval
By HospiMedica International staff writers Posted on 10 Sep 2020 |
Image: South Korea`s Celltrion to Begin Mass Production of Experimental COVID-19 Antibody Drug Ahead of EUA Approval (Photo courtesy of Celltrion Group)
Celltrion Group (Incheon, South Korea) plans to soon begin commercial production of its experimental COVID-19 antiviral antibody treatment even as the company continues to conduct clinical trials of the antibody drug.
Celltrion had completed identification of antibody candidates for an antiviral treatment in April and announced positive pre-clinical results for its COVID-19 antiviral antibody treatment in June, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2. The treatment became the first COVID-19 antibody drug to be tested on humans in South Korea after receiving regulatory approval in July for clinical trials, stated a report by Reuters.
Celltrion has now reportedly completed Phase 1 trial involving 32 volunteers in South Korea and is enrolling an additional nine participants for another Phase 1 study ahead of later stage trials, for which regulatory reviews are underway. The company is conducting separate overseas human trials of its treatment in the UK, which will be followed by global second and third stage trials in COVID-19 patients with mild and moderate symptoms, according to the Reuters report.
“We have confirmed the safety of the antiviral antibody drug in the process of the local Phase 1 clinical trial,” Kwon Ki-sung, head of Celltrion’s R&D unit, told Reuters.
Related Links:
Celltrion Group
Celltrion had completed identification of antibody candidates for an antiviral treatment in April and announced positive pre-clinical results for its COVID-19 antiviral antibody treatment in June, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2. The treatment became the first COVID-19 antibody drug to be tested on humans in South Korea after receiving regulatory approval in July for clinical trials, stated a report by Reuters.
Celltrion has now reportedly completed Phase 1 trial involving 32 volunteers in South Korea and is enrolling an additional nine participants for another Phase 1 study ahead of later stage trials, for which regulatory reviews are underway. The company is conducting separate overseas human trials of its treatment in the UK, which will be followed by global second and third stage trials in COVID-19 patients with mild and moderate symptoms, according to the Reuters report.
“We have confirmed the safety of the antiviral antibody drug in the process of the local Phase 1 clinical trial,” Kwon Ki-sung, head of Celltrion’s R&D unit, told Reuters.
Related Links:
Celltrion Group
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans